Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19031391 | 0.85 | ALDH1A1 (0.63) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL6319718 | 0.84 | ALDH1A1 (0.66) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL28727291 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL2170056 | 0.82 | ALDH1A1 (0.64) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL836745 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL23617613 | 0.81 | NPC1 (0.63) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL21865146 | 0.81 | THRB (0.65) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL12545749 | 0.81 | RECQL (0.65) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| SCHEMBL369480 | 0.81 | ALDH1A1 (0.62) | ALDH1A1RECQLTHRBL3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL3610419 | 0.81 | SMN1; SMN2 (0.63) | ALDH1A1RECQLTHRBL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118880329-A | Acidic copper salt roughening solution for precisely regulating and controlling roughness of copper foil and roughening method | 长江师范学院 | 2024-11-01 | — | — | CN | claimed |
| CN-108395428-B | Benzothiazole-triazole-isatin type compound and synthesis and application thereof | 贵州医科大学 | 2021-02-02 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| CN-102010427-A | Method for preparing cefdinir | CHINA UNION CHEMPHARMA SUZHOU CO LTD | 2011-04-13 | — | — | CN | claimed |
| CN-101974020-A | Method for synthesizing cefdinir | CHINA UNION CHEMPHARMA SUZHOU CO LTD | 2011-02-16 | — | — | CN | claimed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| EP-4706757-A2 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4209490-B1 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12459937-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-04 | — | — | US | disclosed |
| US-20250282773-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250243195-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-6136831-A | ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL AGENTS, ENZYME INHIBITORS | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-1006114-A1 | PYRAZOLE DERIVATIVES AND COX INHIBITORS CONTAINING THEM | Grelan Pharmaceutical Co., Ltd. (JP) | 2000-06-07 | — | — | EP | disclosed |
| US-6071962-A | IN TOPICAL APPLICATIONS TO TREAT VARIOUS SKIN CONDITIONS ATTRIBUTED TO, ACCOMPANIED BY OR EXACERBATED BY ABNORMAL DESQUAMATION INCLUDING DRY SKIN, ICHTHYOSIS, PALMAR AND PLANTAR HYPERKERATOSES, DANDRUFF, LICHEN SIMPLEX CHRONICUS | AVON PRODUCTS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-5847003-A | Oxa acids and related compounds for treating skin conditions | AVON PRODUCTS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5834513-A | TOPICAL COMPOSITION FOR TREATING SKIN CONDITIONS CHARACTERIZED BY ABNORMAL DESQUAMATION | AVON PRODUCTS, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5264611-A | Process for preparing trans-β-aroylacrylic ester | KANEGAFUCHI KAGAKU KABUSHIKI KAISHA (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0494620-A2 | Process for preparing trans-beta-aroylacrylic ester | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459937-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | ALDH1A1 1793/4885RECQL 3809/4885THRB 1362/4885 |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | ALDH1A1 1793/4885RECQL 3809/4885THRB 1362/4885 |
| US-20250282773-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | ALDH1A1 1793/4885RECQL 3809/4885THRB 1362/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ALDH1A1 4757/4885RECQL 3092/4885THRB 4490/4885 |
| US-20250243195-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | ALDH1A1 1793/4885RECQL 3809/4885THRB 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.